Retatrutide vs Every Drug: Comparison Hub
How does retatrutide stack up against every other weight loss option? This comparison hub provides side-by-side data for retatrutide versus every major medication and intervention, based on clinical trial results (Jastreboff et al., NEJM 2023) and published data for each comparator.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Cross-trial comparisons are inherently limited; direct head-to-head studies provide the strongest evidence. Consult your provider for personalized treatment recommendations.
Master Comparison Table
| Treatment | Mechanism | Avg Weight Loss | Administration | FDA Status |
|---|---|---|---|---|
| Retatrutide | GLP-1/GIP/Glucagon | 24.2% | Weekly injection | Phase 3 |
| Tirzepatide (Zepbound) | GLP-1/GIP | 22.5% | Weekly injection | Approved |
| Semaglutide (Wegovy) | GLP-1 | 15-17% | Weekly injection | Approved |
| Liraglutide (Saxenda) | GLP-1 | 5-8% | Daily injection | Approved |
| Contrave | Bupropion/naltrexone | 5-8% | Oral daily | Approved |
| Phentermine | Sympathomimetic | 5-7% | Oral daily | Approved (short-term) |
| Metformin | AMPK activation | 2-5% | Oral daily | Approved (off-label) |
| Gastric sleeve | Surgical restriction | 25-30% | Surgery | Established |
| Gastric bypass | Surgical restriction + malabsorption | 30-35% | Surgery | Established |
| Diet + exercise alone | Behavioral | 3-7% | Lifestyle | N/A |
Detailed Comparison Articles
For in-depth analysis of each comparison, see our dedicated articles:
- Retatrutide vs Semaglutide
- Retatrutide vs Tirzepatide
- Retatrutide vs Ozempic
- Retatrutide vs Wegovy
- Retatrutide vs Contrave
- Retatrutide vs Phentermine
- Retatrutide vs Metformin
- Retatrutide vs Bariatric Surgery
- Retatrutide vs Gastric Sleeve
- Retatrutide vs Gastric Bypass
- Retatrutide vs Saxenda
- Retatrutide vs Berberine
- Retatrutide vs Diet and Exercise
- Retatrutide vs Orforglipron
- Retatrutide vs Amycretin
Key Takeaways
- Retatrutide produces the most weight loss of any medication studied to date
- Only bariatric surgery produces comparable or greater weight loss
- Unlike surgery, retatrutide is reversible and non-invasive
- Older medications (phentermine, Contrave) produce significantly less weight loss
- Retatrutide's GI side effect profile appears favorable compared to semaglutide
- The best treatment depends on individual medical history, goals, insurance, and preferences
GLP-1 Treatment Available Now
While retatrutide is in Phase 3 trials, Trimi offers compounded semaglutide ($125/month) and compounded tirzepatide ($125/month), the two most effective FDA-approved GLP-1 medications. Learn how Trimi works.
Frequently Asked Questions
Is retatrutide the best weight loss drug?
Based on Phase 2 data, retatrutide produces the most average weight loss of any medication. However, "best" depends on individual factors including tolerability, cost, availability, and specific health goals.
Should I wait for retatrutide instead of starting semaglutide or tirzepatide?
Waiting delays treatment of a condition that worsens over time. Starting semaglutide or tirzepatide now provides immediate benefits, and switching to retatrutide later is an option when it becomes available.
Can retatrutide replace bariatric surgery?
For many patients, yes. Retatrutide approaches surgical weight loss results without surgical risks. However, some patients with extreme obesity (BMI 50+) or specific anatomical concerns may still benefit from surgery.
Which is safer: retatrutide or surgery?
Retatrutide is non-invasive and reversible, while surgery carries operative risks including infection, blood clots, and anesthesia complications. However, surgery is a one-time event while retatrutide requires ongoing use.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).